SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. The fireside chat session is scheduled for Wednesday, December 3, in New York, N ...

Core Insights - Boundless Bio is a clinical-stage oncology company focused on developing therapies for oncogene amplified cancers through the study of extrachromosomal DNA (ecDNA) [2] Group 1: Company Overview - Boundless Bio is dedicated to addressing the unmet needs of patients with oncogene amplified tumors, which are linked to ecDNA observed in 14% to 17% of cancer patients [2] - The company is developing ecDNA-directed therapeutic candidates, including BBI-355, a selective CHK1 inhibitor, and BBI-825, a selective RNR inhibitor [2] - Boundless Bio is conducting a phase 1/2 clinical trial named POTENTIATE to evaluate the combination of BBI-355 and BBI-825 in patients with oncogene amplified cancers [2] Group 2: Upcoming Presentation - Boundless Bio will present a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from October 22-26, 2025, in Boston, MA [1] - The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355 targeting unique dependencies of oncogene amplified cancers [1] - The poster session is scheduled for October 23, 2025, from 12:30 PM to 4:00 PM ET, located at Level 2, Exhibit Hall D [1]

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers, addressing a significant unmet medical need [3] - The company is investigating extrachromosomal DNA (ecDNA), which is implicated in oncogene amplification in 14% to 17% of cancer patients [3] Product Development - Boundless Bio is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3] - The next therapeutic candidate, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) and has been evaluated in a Phase 1/2 clinical trial for cancer patients with resistance gene amplifications [3] - The company is also conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable Kinesin degrader [3] Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20 a.m. ET [1][2]

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers by targeting extrachromosomal DNA (ecDNA), which is implicated in 14 to 17% of cancer cases [3]. - The company is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3]. - Boundless Bio utilizes its Spyglass platform for additional programs that are in preclinical development and discovery [3]. Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at Leerink's Global Healthcare Conference on March 12, 2025, at 11:20 a.m. ET in Miami, FL [2]. - A live and archived webcast of the session will be available on Boundless Bio's website under the "Events & Presentations" section [2].